KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Income from Continuing Operations (2020 - 2025)

Historic Income from Continuing Operations for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$162.3 million.

  • Recursion Pharmaceuticals' Income from Continuing Operations fell 6929.22% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 8942.19%. This contributed to the annual value of -$463.7 million for FY2024, which is 4133.16% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Income from Continuing Operations of -$162.3 million as of Q3 2025, which was down 6929.22% from -$171.9 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Income from Continuing Operations' 5-year high stood at -$30.5 million during Q1 2021, with a 5-year trough of -$202.5 million in Q1 2025.
  • For the 5-year period, Recursion Pharmaceuticals' Income from Continuing Operations averaged around -$92.5 million, with its median value being -$76.7 million (2023).
  • Per our database at Business Quant, Recursion Pharmaceuticals' Income from Continuing Operations plummeted by 15393.85% in 2021 and then skyrocketed by 612.38% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$65.0 million in 2021, then grew by 6.12% to -$61.0 million in 2022, then crashed by 52.5% to -$93.0 million in 2023, then crashed by 92.38% to -$178.9 million in 2024, then increased by 9.31% to -$162.3 million in 2025.
  • Its Income from Continuing Operations stands at -$162.3 million for Q3 2025, versus -$171.9 million for Q2 2025 and -$202.5 million for Q1 2025.